Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Cantor Fitzgerald
Healthtrust
Express Scripts
Baxter
Boehringer Ingelheim
Medtronic
Chinese Patent Office
Mallinckrodt
Deloitte

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,431,155

« Back to Dashboard

Which drugs does patent 8,431,155 protect, and when does it expire?

Patent 8,431,155 protects CYCLOSET and is included in one NDA.

This patent has thirteen patent family members in ten countries.
Summary for Patent: 8,431,155
Title:Bromocriptine formulations
Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.
Inventor(s): Cincotta; Anthony H. (Tiverton, RI), Bowe; Craig Michael (Encinitas, CA), Stearns; Paul Clark (San Diego, CA), Weston; Laura Jean (Escondido, CA)
Assignee: VeroScience LLC (Tiverton, RI)
Application Number:13/460,452
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use; Device;

Drugs Protected by US Patent 8,431,155

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,431,155

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,700,555 Bromocriptine formulations ➤ Try a Free Trial
8,613,947 Bromocriptine formulations ➤ Try a Free Trial
9,192,576 Bromocriptine formulations ➤ Try a Free Trial
9,522,117 Bromocriptine formulations ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,431,155

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 2014013158 ➤ Try a Free Trial
South Korea 101593360 ➤ Try a Free Trial
South Korea 20150006461 ➤ Try a Free Trial
Japan 6180515 ➤ Try a Free Trial
Japan 2015515984 ➤ Try a Free Trial
Hong Kong 1208173 ➤ Try a Free Trial
European Patent Office 2844229 ➤ Try a Free Trial
Canada 2872300 ➤ Try a Free Trial
Australia 2016202572 ➤ Try a Free Trial
Australia 2013256558 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
Express Scripts
Medtronic
Citi
US Department of Justice
Dow
Fuji
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot